Publicaciones (48) Publicaciones de David Santamaría Velilla

2024

  1. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

    Nature, Vol. 629, Núm. 8013, pp. 919-926

  2. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma

    Cell Reports Medicine, Vol. 5, Núm. 8

  3. Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node

    Molecular Oncology, Vol. 18, Núm. 6, pp. 1355-1377

  4. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

    Nature Communications, Vol. 15, Núm. 1

  5. Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 121, Núm. 36

2023

  1. Reuniting philosophy and science to advance cancer research

    Biological Reviews, Vol. 98, Núm. 5, pp. 1668-1686

2022

  1. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 28, Núm. 8, pp. 1640-1650

  2. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)

    Cancer Treatment Reviews, Vol. 103

2021

  1. Gene expression profiling as a potential tool for precision oncology in non-small cell lung cancer

    Cancers, Vol. 13, Núm. 19

  2. RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression

    Cancer Cell

  3. Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer

    Trends in Cancer, Vol. 7, Núm. 5, pp. 410-429

2020

  1. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma

    JCI Insight, Vol. 5, Núm. 15

  2. Meeting report – first discoidin domain receptors meeting

    Journal of Cell Science

  3. Squamous differentiation requires G2/mitosis slippage to avoid apoptosis

    Cell Death and Differentiation, Vol. 27, Núm. 8, pp. 2451-2467

  4. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 39, pp. 24415-24426

2019

  1. Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance

    Cell Adhesion and Migration, Vol. 12, Núm. 4, pp. 394-397

  2. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

    Cell, Vol. 172, Núm. 4, pp. 857-868.e15

  3. Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer

    Lung Cancer

2017

  1. A Braf kinase-inactive mutant induces lung adenocarcinoma

    Nature, Vol. 548, Núm. 7666, pp. 239-243